The CEO of Pfizer was brutally booed at a press conference Donald Trump held in the White House in commemoration of Black History Month in an awkward moment that involved several similar introductions

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez.

Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) across all global markets, citing weak demand. "Pfizer has made the decision to cease further development and commercialization activities with respect to Beqvez for several reasons,